Inflammatory bowel disease—From mechanisms to treatment strategies

References

• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet. 2007; 369:1641.
   PubMed Web of Science ®Google Scholar
• Brain O, Travis SPL. Therapy of ulcerative colitis: State of the art. Curr Opin Gastroenterol. 2008; 24:469–474 doi: 410.1097/MOG.1090b1013e3282ff1090dd1095.
   PubMed Web of Science ®Google Scholar
• Waldner MJ, Neurath MF. Novel cytokine-targeted therapies and intestinal inflammation. Curr Opin Pharmacol. 2009; 9:702.
   PubMed Web of Science ®Google Scholar
• Hugot J-P, Chamaillard M, Zouali H, Lesage S, Cezard J-P, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599–603.
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411:603–606.
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006; 314:1461–1463.
   PubMed Web of Science ®Google Scholar
• Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ, Brant SR. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007; 39:596–604.
   PubMed Web of Science ®Google Scholar
• Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, Günther S, Prescott NJ, Onnie CM, Häsler R, Sipos B, Fölsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007; 39:207–211.
   PubMed Web of Science ®Google Scholar
• Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut. 1988; 29:990–996.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Shanahan F. Disorders of a modern lifestyle: Reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008; 57:1185–1191.
   PubMed Web of Science ®Google Scholar
• Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005; 122:107.
   PubMed Web of Science ®Google Scholar
• Bouskra D, Brézillon C, Bérard M, Werts C, Varona R, Boneca IG, Eberl G. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature. 2008; 456:507–510.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008; 134:577.
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002; 122:44.
   PubMed Web of Science ®Google Scholar
• Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser A-L, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent–invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004; 127:412–421.
   PubMed Web of Science ®Google Scholar
• Abubakar I, Myhill D, Aliyu SH, Hunter PR. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: A systematic review and meta-analysis. Inflamm Bowel Dis. 2008; 14:401–410.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin N Amer. 2009; 38:711.
   PubMed Web of Science ®Google Scholar
• Clayton EM, Rea MC, Shanahan F, Quigley EMM, Kiely B, Hill C, Ross RP. The vexed relationship between Clostridium difficile and inflammatory bowel disease: An assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009; 104:1162–1169.
   PubMed Web of Science ®Google Scholar
• Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular–phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007; 104:13780–13785.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008; 105:16731–16736.
   PubMed Web of Science ®Google Scholar
• Ryu JH, Kim SH, Lee HY, Bai JY, Nam YD, Bae JW, Lee DG, Shin SC, Ha EM, Lee WJ. Innate immune homeostasis by the homeobox gene caudal and commensal-gut mutualism in Drosophila. Science. 2008; 319:777–782.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Meek B, Doi Y, Muramatsu M, Chiba T, Honjo T, Fagarasan S. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci USA. 2004; 101:1981–1986.
   PubMed Web of Science ®Google Scholar
• Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, Glimcher LH. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007; 131:33–45.
   PubMed Web of Science ®Google Scholar
• Knight P, Campbell BJ, Rhodes JM. Host–bacteria interaction in inflammatory bowel disease. Br Med Bull. 2008; 88:95–113.
   PubMed Web of Science ®Google Scholar
• Smith AM, Rahman FZ, Hayee BH, Graham SJ, Marks DJB, Sewell GW, Palmer CD, Wilde J, Foxwell BM, Gloger IS, Sweeting T, Marsh M, Walker AP, Bloom SL, Segal AW. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med. 2009; 206:1883–1897.
   PubMed Web of Science ®Google Scholar
• Marks D, Rahman F, Sewell G, Segal A. Crohn's disease: An immune deficiency state. Clin Rev Allergy Immunol. 2010; 38 1: 20–31.
   PubMed Web of Science ®Google Scholar
• Sewell GW, Marks DJB, Segal AW. The immunopathogenesis of Crohn's disease: A three-stage model. Curr Opin Immunol. 2009; 21:506–513.
   PubMed Web of Science ®Google Scholar
• Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldt D, Nikolaus S, Rosenstiel P, Krawczak M, Schreiber S. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet. 2008; 40:713–715.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ, Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008; 40:955–962.
   PubMed Web of Science ®Google Scholar
• Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, Rosenstiel P, Albrecht M, Croucher PJ, Seegert D, Nikolaus S, Hampe J, Lengauer T, Pierrou S, Foelsch UR, Mathew CG, Lagerstrom-Fermer M, Schreiber S. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004; 36:476–480.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, Phillips A, Wesley E, Parnell K, Zhang H, Drummond H, Nimmo ER, Massey D, Blaszczyk K, Elliott T, Cotterill L, Dallal H, Lobo AJ, Mowat C, Sanderson JD, Jewell DP, Newman WG, Edwards C, Ahmad T, Mansfield JC, Satsangi J, Parkes M, Mathew CG, Donnelly P, Peltonen L, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Duncanson A, Jankowski J, Markus HS, Mathew CG, McCarthy MI, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Samani N, Trembath RC, Viswanathan AC, Wood N, Spencer CC, Barrett JC, Bellenguez C, Davison D, Freeman C, Strange A, Donnelly P, Langford C, Hunt SE, Edkins S, Gwilliam R, Blackburn H, Bumpstead SJ, Dronov S, Gillman M, Gray E, Hammond N, Jayakumar A, McCann OT, Liddle J, Perez ML, Potter SC, Ravindrarajah R, Ricketts M, Waller M, Weston P, Widaa S, Whittaker P, Deloukas P, Peltonen L, Mathew CG, Blackwell JM, Brown MA, Corvin A, McCarthy MI, Spencer CC, Attwood AP, Stephens J, Sambrook J, Ouwehand WH, McArdle WL, Ring SM, Strachan DP, Wellcome Trust Case Control Consortium 2. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009; 41:1330–1334.
   PubMed Web of Science ®Google Scholar
• Kaser A, Lee A-H, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EE, Higgins DE, Schreiber S, Glimcher LH, Blumberg RS. XBP1 links ER Stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell. 2008; 134:743–756.
   PubMed Web of Science ®Google Scholar
• McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P, Zody MC, Hall JL, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Rioux JD, Altshuler D, Daly MJ, Xavier RJ. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet. 2008; 40:1107–1112.
   PubMed Web of Science ®Google Scholar
• Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Roucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002; 122:867–874.
   PubMed Web of Science ®Google Scholar
• Gutierrez O, Pipaon C, Inohara N, Fontalba A, Ogura Y, Prosper F, Nunez G, Fernandez-Luna JL. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation. J Biol Chem. 2002; 277:41701–41705.
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Suzuki M, Reinecker H-C, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology. 2003; 124:993.
   PubMed Web of Science ®Google Scholar
• Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, Ogunbiyi O, Nuñez G, Keshav S. Crohn's disease and the NOD2 gene: A role for paneth cells. Gastroenterology. 2003; 125:47–57.
   PubMed Web of Science ®Google Scholar
• Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nuñez G. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003; 278:5509–5512.
   PubMed Web of Science ®Google Scholar
• Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology. 2003; 124:521.
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, Flavell RA. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005; 307:731–734.
   PubMed Web of Science ®Google Scholar
• Maeda S, Hsu L-C, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L, Karin M. Nod2 mutation in Crohn's disease potentiates NF-{kappa}B activity and IL-1{beta} processing. Science. 2005; 307:734–738.
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schröder JM, Bevins CL, Fellermann K, Stange EF. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal {alpha}-defensin expression. Gut. 2004; 53:1658–1664.
   PubMed Web of Science ®Google Scholar
• Zuzana Z, van Beelen AJ, de Kort F, Moerland PD, Ver Loren van Themaat E, te Velde AA, van Deventer SJ, de Jong EC, Hommes DW. Muramyl dipeptide-induced differential gene expression in NOD2 mutant and wild-type Crohn's disease patient-derived dendritic cells. Inflam Bowel Dis. 2008; 14:186–194.
   PubMed Web of Science ®Google Scholar
• Mizushima N. Autophagy: Process and function. Genes Dev. 2007; 21:2861–2873.
   PubMed Web of Science ®Google Scholar
• Schmid D, Münz C. Innate and adaptive immunity through autophagy. Immunity. 2007; 27:11.
   PubMed Web of Science ®Google Scholar
• Kuballa P, Huett A, Rioux JD, Daly MJ, Xavier RJ. Impaired Autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS One. 2008; 3:e3391.
   PubMed Web of Science ®Google Scholar
• Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HWIV. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature. 2008; 456:259–263.
   PubMed Web of Science ®Google Scholar
• Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, Omori H, Noda T, Yamamoto N, Komatsu M, Tanaka K, Kawai T, Tsujimura T, Takeuchi O, Yoshimori T, Akira S. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature. 2008; 456:264–268.
   PubMed Web of Science ®Google Scholar
• Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science. 2006; 313:1438–1441.
   PubMed Web of Science ®Google Scholar
• Collazo CM, Yap GS, Sempowski GD, Lusby KC, Tessarollo L, Woude GF, Sher A, Taylor GA. Inactivation of Lrg-47 and Irg-47 reveals a family of interferon {gamma}-Inducible Genes with essential, pathogen-specific roles in resistance to infection. J Exp Med. 2001; 194:181–188.
   PubMed Web of Science ®Google Scholar
• Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, Inohara N, Núñez G, Kishi Y, Koike Y, Shimosegawa T, Shimoyama T, Hibi T. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology. 2002; 123:86–91.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata A. Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients. J Human Genet. 2007; 52:575.
   PubMed Web of Science ®Google Scholar
• Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C, Barrett JC, Cummings FR, Drummond H, Lees CW, Onnie CM, Hanson CE, Blaszczyk K, Inouye M, Ewels P, Ravindrarajah R, Keniry A, Hunt S, Carter M, Watkins N, Ouwehand W, Lewis CM, Cardon L, Lobo A, Forbes A, Sanderson J, Jewell DP, Mansfield JC, Deloukas P, Mathew CG, Parkes M, Satsangi J, Wellcome Trust Case Control Consortium. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet. 2008; 40:710–712.
   PubMed Web of Science ®Google Scholar
• Festen EAM, Goyette P, Scott R, Annese V, Zhernakova A, Lian J, Lefèbvre C, Brant SR, Cho JH, Silverberg MS, Taylor KD, de Jong DJ, Stokkers PC, Mcgovern D, Palmieri O, Achkar JP, Xavier RJ, Daly MJ, Duerr RH, Wijmenga C, Weersma RK, Rioux JD. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut. 2009; 58:799–804.
   PubMedGoogle Scholar
• Silverberg MS, Cho JH, Rioux JD, McGovern DPB, Wu J, Annese V, Achkar JP, Goyette P, Scott R, Xu W, Barmada MM, Klei L, Daly MJ, Abraham C, Bayless TM, Bossa F, Griffiths AM, Ippoliti AF, Lahaie RG, Latiano A, Paré P, Proctor DD, Regueiro MD, Steinhart AH, Targan SR, Schumm LP, Kistner EO, Lee AT, Gregersen PK, Rotter JI, Brant SR, Taylor KD, Roeder K, Duerr RH. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009; 41:216–220.
   PubMed Web of Science ®Google Scholar
• Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, Yim S, Lambert G, Kurotani R, Nagashima K, Gonzalez FJ, Inoue Y. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:908–920.
   PubMed Web of Science ®Google Scholar
• Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 1995; 270:1203–1207.
   PubMed Web of Science ®Google Scholar
• Pabst O, Forster R, Lipp M, Engel H, Arnold H-H. NKX2.3 is required for MAdCAM-1 expression and homing of lymphocytes in spleen and mucosa-associated lymphoid tissue. EMBO J. 2000; 19:2015.
   PubMed Web of Science ®Google Scholar
• Tarlinton D, Light A, Metcalf D, Harvey RP, Robb L. Architectural defects in the spleens of Nkx2-3-deficient mice are intrinsic and associated with defects in both B cell maturation and T cell-dependent immune responses. J Immunol. 2003; 170:4002–4010.
   PubMed Web of Science ®Google Scholar
• Shanahan F. Therapeutic implications of manipulating and mining the microbiota. J Physiol. 2009; 587:4175–4179.
   PubMed Web of Science ®Google Scholar
• Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008; 453:620.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Carding SR. Inflammatory bowel disease: Cause and immunobiology. Lancet. 2007; 369:1627.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004; 113:1490–1497.
   PubMed Web of Science ®Google Scholar
• Melgar S, Yeung MW, Bas A, Forsberg G, Suhr O, Öberg A, Hammarstrom S, Danielsson A, Hammarstrom ML. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol. 2003; 134:127–137.
   PubMed Web of Science ®Google Scholar
• Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006; 203:2473–2483.
   PubMed Web of Science ®Google Scholar
• Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, Cua DJ, Powrie F, Cheever AW, Maloy KJ, Sher A. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med. 2006; 203:2485–2494.
   PubMed Web of Science ®Google Scholar
• Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006; 25:309–318.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, Neurath MF, Strober W, Mannon PJ. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflam Bowel Dis. 2006; 12:9–15.
   PubMed Web of Science ®Google Scholar
• Becker C, Dornhoff H, Neufert C, Fantini MC, Wirtz S, Huebner S, Nikolaev A, Lehr HA, Murphy AJ, Valenzuela DM, Yancopoulos GD, Galle PR, Karow M, Neurath MF. Cutting edge: IL-23 Cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol. 2006; 177:2760–2764.
   PubMed Web of Science ®Google Scholar
• Izcue A, Hue S, Buonocore S, Arancibia-Cárcamo CV, Ahern PP, Iwakura Y, Maloy KJ, Powrie F. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity. 2008; 28:559–570.
   PubMed Web of Science ®Google Scholar
• Pene J, Chevalier S, Preisser L, Venereau E, Guilleux M-H, Ghannam S, Molès JP, Danger Y, Ravon E, Lesaux S, Yssel H, Gascan H. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008; 180:7423–7430.
   PubMed Web of Science ®Google Scholar
• Dambacher J, Beigel F, Zitzmann K, de Toni E, Goke B, Diepolder HM, Auernhammer CJ, Brand S. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2008; 58 9: 1207–1217.
   PubMed Web of Science ®Google Scholar
• Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP, Raskin L, Desai B, Faubion WA, de Waal Malefyt R, Pierce RH, McClanahan T, Kastelein RA. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med. 2009; 206:525–534.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua D. Th17 cell differentiation: The long and winding road. Immunity. 2008; 28:445.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut. 2008; 57:1682–1689.
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6:1133–1141.
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Filì L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007; 204:1849–1861.
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007; 8:639–646.
   PubMed Web of Science ®Google Scholar
• Divangahi M, Mostowy S, Coulombe F, Kozak R, Guillot L, Veyrier F, Kobayashi KS, Flavell RA, Gros P, Behr MA. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol. 2008; 181:7157–7165.
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003; 52:65–70.
   PubMed Web of Science ®Google Scholar
• Ke X-S, Liu C-M, Liu D-P, Liang C-C. MicroRNAs: Key participants in gene regulatory networks. Curr Opin Chem Biol. 2003; 7:516.
   Google Scholar
• Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009; 136:215.
   PubMed Web of Science ®Google Scholar
• Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004; 303:83–86.
   PubMed Web of Science ®Google Scholar
• Li Q-J, Chau J, Ebert PJR, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P, Klein LO, Davis MM, Chen CZ. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007; 129:147–161.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4:499.
   PubMed Web of Science ®Google Scholar
• Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006; 103:12481–12486.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ, Dougan G, Turner M, Bradley A. Requirement of bic/microRNA-155 for normal immune function. Science. 2007; 316:608–611.
   PubMed Web of Science ®Google Scholar
• Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. Cutting edge: The Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol. 2009; 182:2578–2582.
   PubMed Web of Science ®Google Scholar
• Cobb BS, Hertweck A, Smith J, O'Connor E, Graf D, Cook T, Smale ST, Sakaguchi S, Livesey FJ, Fisher AG, Merkenschlager M. A role for Dicer in immune regulation. J Exp Med. 2006; 203:2519–2527.
   PubMed Web of Science ®Google Scholar
• Chong MM, Rasmussen JP, Rudensky AY, Littman DR. The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med. 2008; 205:2005.
   PubMed Web of Science ®Google Scholar
• Mattes J, Collison A, Plank M, Phipps S, Foster PS. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci USA. 2009; 106:18704–18709.
   PubMed Web of Science ®Google Scholar
• Moschos S, Williams A, Perry M, Birrell M, Belvisi M, Lindsay M. Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. BMC Genom. 2007; 8:240.
   PubMed Web of Science ®Google Scholar
• Worm J, Stenvang J, Petri A, Frederiksen KS, Obad S, Elmen J, Hedtjärn M, Straarup EM, Hansen JB, Kauppinen S. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp beta and down-regulation of G-CSF. Nucl Acids Res. 2009; 37:5784–5792.
   PubMed Web of Science ®Google Scholar
• Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, Li Z, Wu Z, Pei G. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009; 10 12: 1252–1259.
   PubMed Web of Science ®Google Scholar
• Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, Brant SR, Chakravarti S, Kwon JH. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2[alpha]. Gastroenterology. 2008; 135:1624–1635.
   PubMed Web of Science ®Google Scholar
• Ceppi M, Pereira PM, Dunand-Sauthier I, Barras EI, Reith W, Santos MA, Pierre P. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA. 2009; 106:2735–2740.
   PubMed Web of Science ®Google Scholar
• Souza HS, Elia CCS, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha 4beta 7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999; 45:856–863.
   PubMed Web of Science ®Google Scholar
• Jesús R-N, Gezahegn G, Klaus L. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1715–1735.
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003; 348:15–23.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005; 353:1912–1925.
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol. 2009; 10:816–824.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JWD, Cohen A, Bitton A, Baker J, Dubé R, Landau SB, Vandervoort MK, Parikh A. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the [alpha]4[beta]7 integrin. Clin Gastroenterol Hepatol. 2008; 6:1370–1377.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JWD, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Treatment of ulcerative colitis with a humanized antibody to the {alpha}4{beta}7 integrin. N Engl J Med. 2005; 352:2499–2507.
   PubMed Web of Science ®Google Scholar
• Cortijo J, Sanz MJ, Iranzo A, Montesinos JL, Nabah YN, Alfón J, Gómez LA, Merlos M, Morcillo EJ. A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. Br J Pharmacol. 2006; 147:661–670.
   PubMed Web of Science ®Google Scholar
• Okigami H, Takeshita K, Tajimi M, Komura H, Albers M, Lehmann TE, Rölle T, Bacon KB. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4. Euro J Pharmacol. 2007; 559:202–209.
   PubMed Web of Science ®Google Scholar
• Glasner J, Blum H, Wehner V, Stilz HU, Humphries JD, Curley GP, Mould AP, Humphries MJ, Hallmann R, Röllinghoff M, Gessner A. A small molecule {alpha}4{beta}1 antagonist prevents development of murine lyme arthritis without affecting protective immunity. J Immunol. 2005; 175:4724–4734.
   PubMed Web of Science ®Google Scholar
• Hijazi Y, Welker H, Dorr AE, Tang J-P, Blain R, Renzetti LM, Abbas R. Pharmacokinetics, safety, and tolerability of R411, a dual {alpha}4{beta}1–{alpha}4{beta}7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J Clin Pharmacol. 2004; 44:1368–1378.
   PubMed Web of Science ®Google Scholar
• Farooq SM, Stillie R, Svensson M, Svanborg C, Strieter RM, Stadnyk AW. Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis. J Pharmacol Exper Therap. 2009; 329:123–129.
   PubMed Web of Science ®Google Scholar
• Bento AF, Leite DFP, Claudino RF, Hara DB, Leal PC, Calixto JB. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol. 2008; 84:1213–1221.
   PubMed Web of Science ®Google Scholar
• Rivera-Nieves J, Ho J, Bamias G, Ivashkina N, Ley K, Oppermann M, Cominelli F. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology. 2006; 131:1518–1529.
   PubMed Web of Science ®Google Scholar
• Fortun PJ, Hawkey CJ. The role of stem cell transplantation in inflammatory bowel disease. Autoimmunity. 2008; 41:654–659.
   PubMed Web of Science ®Google Scholar
• Oyama Y, Craig RM, Traynor AE, Quigley K, Statkute L, Halverson A, Brush M, Verda L, Kowalska B, Krosnjar N, Kletzel M, Whitington PF, Burt RK. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology. 2005; 128:552–563.
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Annaloro C, Ardizzone S, Onida F, Volpe AD, Clerici M, Usardi P, Greco S, Maconi G, Porro GB, Deliliers GL. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut. 2008; 57:211–217.
   PubMed Web of Science ®Google Scholar
• Glocker E-O, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361:2033–2045.
   PubMed Web of Science ®Google Scholar
• Caplan AI. Why are MSCs therapeutic? New data: New insight. J Pathol. 2009; 217:318–324.
   PubMed Web of Science ®Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008; 8:726.
   PubMed Web of Science ®Google Scholar
• Brittan M, Chance V, Elia G, Poulsom R, Alison MR, MacDonald TT, Wright NA. A regenerative role for bone marrow following experimental colitis: Contribution to neovasculogenesis and myofibroblasts. Gastroenterology. 2005; 128:1984–1995.
   PubMed Web of Science ®Google Scholar
• Bamba S, Lee CY, Brittan M, Preston SL, Direkze NC, Poulsom R, Alison MR, Wright NA, Otto WR. Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice. J Pathol. 2006; 209:265–273.
   PubMed Web of Science ®Google Scholar
• Yabana T, Arimura Y, Tanaka H, Goto A, Hosokawa M, Nagaishi K, Yamashita K, Yamamoto H, Adachi Y, Sasaki Y, Isobe M, Fujimiya M, Imai K, Shinomura Y. Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J Pathol. 2009; 218:350–359.
   PubMed Web of Science ®Google Scholar
• González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009; 136:978.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009; 58:929–939.
   PubMed Web of Science ®Google Scholar
• García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn's Fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005; 48:1416.
   PubMed Web of Science ®Google Scholar
• O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006; 7:688–693.
   PubMed Web of Science ®Google Scholar
• Molly P, Robert B. Use of antibiotics in the treatment of inflammatory bowel disease. Inflam Bowel Dis. 2006; 12:651–664.
   PubMed Web of Science ®Google Scholar
• Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: A systematic review of randomised controlled trials. Lancet. 2007; 369:1614.
   PubMed Web of Science ®Google Scholar
• Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006; 101:1581.
   PubMed Web of Science ®Google Scholar
• Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am J Gastroenterol. 2009; 104:1033.
   PubMed Web of Science ®Google Scholar
• Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: A review of clinical trials. Proc Nutr Soc. 2007; 66:307–315.
   PubMed Web of Science ®Google Scholar
• Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CGM. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA. 2007; 104:7617–7621.
   PubMed Web of Science ®Google Scholar
• Sonnenburg JL, Chen CTL, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol. 2006; 4:e413.
   PubMed Web of Science ®Google Scholar
• Mahowald MA, Rey FE, Seedorf H, Turnbaugh PJ, Fulton RS, Wollam A, Shah N, Wang C, Magrini V, Wilson RK, Cantarel BL, Coutinho PM, Henrissat B, Crock LW, Russell A, Verberkmoes NC, Hettich RL, Gordon JI. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci USA. 2009; 106:5859–5864.
   PubMed Web of Science ®Google Scholar
• Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000; 289:1352–1355.
   PubMed Web of Science ®Google Scholar
• Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4:754–759.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 2009; 3 1: 49–56.
   PubMed Web of Science ®Google Scholar